Efficacy and acceptability of the new oral phosphate binder Lenziaren registered in healthy cats fed a renal diet

The efficacy and acceptability of the new oral phosphate binder Lenziaren registered (SBR759) were evaluated in healthy cats fed with a commercial diet containing low amounts of phosphate ('renal diet'). Lenziaren registered at 0.125, 0.25, 0.5 and 1 g/day was compared to a reference product Lantharenol registered (3.0 g/day) and a placebo in a masked, randomized, parallel-group design study in 36 cats (n = 6 per group). All products were mixed with the ration which was fed once daily for 28 days. Lenziaren registered produced significant dose-related reductions in serum and urine phosphate concentrations, faecal apparent phosphorus digestibility and fractional urinary phosphate excretion. Cats administered Lenziaren registered consumed significantly less food than the placebo group, but this had no negative impact on body weight or acceptability assessments. When compared to the positive control, Lantharenol registered , Lenziaren registered was significantly more acceptable (0.125, 0.5 and 1.0 g/day doses), was associated with higher food consumption (0.125, 0.5 and 1.0 g/day doses) and had greater efficacy in reducing serum phosphate (0.5 and 1.0 g/day) and urine phosphate concentrations (1.0 g/day). In conclusion, Lenziaren registered was an effective oral phosphate binder in healthy cats fed with a renal diet. Lenziaren registered was well accepted and tolerated. Dosages of 0.25-1.0 g/cat per day are recommended for clinical testing.